Approach to Lipid Management in the Patient With Diabetes
- 11 January 2025
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (6) , 1740-1755
Abstract
Diabetes is associated with increased atherosclerotic cardiovascular disease (ASCVD) risk, a leading cause of morbidity and mortality. Disordered lipid metabolism is a major contributor to ASCVD risk in diabetes. Dyslipidemia in type 2 diabetes is characterized by hypertriglyceridemia, low high-density lipoprotein cholesterol and the presence of small, dense low-density lipoprotein particles. Statins have demonstrated longstanding benefit for reducing ASCVD risk in individuals with diabetes. Newer agents for add-on therapies to statins are now available for additional cardiovascular risk reduction. In this clinical overview, we review the pathogenesis of dyslipidemia in both type 1 and 2 diabetes and provide an update on the management of lipids in the individual with diabetes. We discuss the importance of appropriate risk stratification and individualized treatment selection and the need to avoid therapy inertia to mitigate cardiovascular risk. We also address lipid-related effects of glycemic-lowering therapies.Keywords
This publication has 130 references indexed in Scilit:
- Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery DiseaseJAMA Network Open, 2023
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular RiskJAMA, 2020
- Statin users have an elevated risk of dysglycemia and new‐onset‐diabetesDiabetes/Metabolism Research and Reviews, 2019
- Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid ObesityJAMA, 2018
- Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid ObesityJAMA, 2018
- Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 DiabetesJAMA, 2016
- Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient‐level pooled analysisDiabetes/Metabolism Research and Reviews, 2011
- Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 DiabetesJAMA, 2008
- Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 DiabetesJAMA, 2006
- The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patientsDiabetologia, 2006